Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Moderna Inc. - news published 664 - readings 14.266

BACK

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

SEC FORM 4SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 Check this box if no long ...

22.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

15.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

SEC.gov | Request Rate Threshold Exceeded U.S. Securities and Exchange Commission Your Request Originates from an Undeclared Automated Tool To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Your request has been identified as part of a network of automated tools outside of the acceptable policy and ...

15.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

11.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

11.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

11.06.2021

Moderna Inc.

Statement on Myocarditis and Pericarditis

June 11, 2021 at 1:00 PM EDT PDF Version Moderna is aware of reports of myocarditis and/or pericarditis following administration of mRNA vaccines against COVID-19, including data presented by the U.S. Centers for Disease Control and Prevention on June 10, 2021 at the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee meeting. After ...

11.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

09.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Moderna Inc. published this content on 09 June 2021 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 09 June 2021 20:18:37 UTC .

09.06.2021

Moderna Inc.

Initial Insider Trading Report (SEC Filing - 3)

SEC.gov | File Unavailable Skip to Main Content U.S. Securities and Exchange Commission SEC.gov Search FormSearch SEC.gov Company Filings | More Search Options About What We Do Commissioners Securities Laws SEC Docket Reports and Publications Careers Contact Divisions Corporation Finance Enforcement Investment Management Economic and Risk Analysis Trading and Markets National E ...

09.06.2021

Moderna Inc.

CEO Investor Forum Presentation

Commitment to Sustainability Stéphan e Ba ncel, CEO June 7, 2021 Forward-looking statements and Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company's efforts to develop the Moderna COVID-19 Vaccine against SARS- CoV-2, as well as vac ...

07.06.2021

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

04.06.2021

Moderna Inc.

Science Day Presentation

Fourth Annual Science Day May 27, 2021 Forward-looking statements and Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for mRNA as a new class of medicines and the product opportunity, the probability of technical success, resear ...

27.05.2021

Moderna Inc.

Moderna 1Q 2021 Earnings Call Presentation

DNA mRNA Protein Business Updates First Quarter 2021 Financial Results May 6, 2021 Forward-looking statements and Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including statements regarding: the Company's development of the Moderna COVID-19 Vaccine (mRNA-1273); the numb ...

06.05.2021

Moderna Inc.

Vaccines Day Presentation

Prophylactic vaccines Encoded CMV Germline mRNA(s) hMPV/ Zika VLP SARS- HIV PIV3 EBV Flu CoV-2 RSV HIV gp160 Nipah Encoded mRNA(s) Ribosome Protein chain(s) Second Annual Vaccines Day Wednesday, April 14 th , 2021 Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of ...

14.04.2021

Moderna Inc. - news published 664 - readings 14.266

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Statement on Myocarditis and Pericarditis

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Initial Insider Trading Report (SEC Filing - 3)

Moderna Inc.

CEO Investor Forum Presentation

Moderna Inc.

Insider Trading Report (SEC Filing - 4)

Moderna Inc.

Science Day Presentation

Moderna Inc.

Moderna 1Q 2021 Earnings Call Presentation

Moderna Inc.

Vaccines Day Presentation

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member